Login to Your Account


Thursday, April 7, 2016

Lumos Pharma Inc., of Austin, Texas, said it completed a $34 million series B financing to support clinical trials and commercialization of lead compound LUM-001 in creatine transporter deficiency, the leading cause of X-linked mental retardation in males after fragile X syndrome.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription